Merck & Co Inc at Citi BioPharma Conference Transcript
So delighted to introduce our next speaker, Dr. Marjorie Green at Merck, who heads Oncology Development. Marjorie came 5 months ago from Seagen. We're also joined by representatives of Merck's IR team.
I'm going to give opportunities for those of you in the audience to ask questions throughout the day. So just raise your hand if you would like me to put a question to Marjorie, and we can kind of go from there.
Maybe we start with TIGIT, or TIGIT, as Roger used to like referring it. I like TIGIT because it rhymes with the title of the first report we wrote about it. TIGIT, we totally dig it. And on that note, Roche inversely disclosed their Phase II data, which is a whole another story.
But it's quite informative, and you obviously, did biostatistical analysis, trying to assess the probability of hitting, depending on what you assume for the alpha spend was for the PFS region and what you think the hazard ratio is going to be for the remaining patients. It's not complicated stuff.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
